Glenmark Pharmaceuticals Limited
HDFC Mutual Fund entered Glenmark Pharmaceuticals with 1,75,66,947 shares, a 6.22% stake worth ₹3,924.96 Cr. This move resulted in crossing the 5% disclosure threshold.
A global research-led pharmaceutical company, Glenmark operates across generics, specialty, and over-the-counter business segments with a presence in more than 80 countries worldwide. The company develops and manufactures pharmaceutical products serving patients across multiple therapeutic areas including oncology, dermatology, and respiratory care. Its distinctive strength lies in combining generic drug manufacturing capabilities with specialty pharmaceutical development and maintaining a robust international distribution network across developed and emerging markets.
One of India's oldest and most trusted AMCs with over Rs 7.5 lakh crore in AUM. Founded in 1999 as a joint venture between HDFC Bank and Standard Life. MD and CEO Navneet Munot, formerly CIO of SBI MF, has reinforced the quality and compounding philosophy across equity schemes. HDFC Flexi Cap Fund and HDFC Mid-Cap Opportunities Fund are among the largest actively managed equity schemes in India.